@MichaelCWilder There is evidence to suggest, that #LongCovid and #Covid19 can be cured: https://t.co/oDOKPLCGp1 But prof. Hannelore Ehrenreich couldn't get funding to try it out in 2020 : https://t.co/kOOyp5QBPs https://t.co/AvsGLddgWM Where has all
Erythropoietin as candidate for supportive treatment of severe COVID-19 | Molecular Medicine | Full Text https://t.co/wtuSTD78kH
#Erythropoietin decreases rapidly upon returning to sea level after chronic exposure to altitude. Acute #hypoxia can provide an additional stimulus to prevent lowering of EPO.
https://t.co/BEjRWBIhBE #ImmunoMetabolic Therapy Dr. Rómulo Daniel Grimaldes Jiménez Internist Medicine
@claudia_ellert @LinkedIn Neue Erkentnisse bei Epo gegen Covid-19? https://t.co/G1hGdL6d1a https://t.co/7gJmL9WeF1
Worth a serious trial-decades of experience with Epo. @narendramodi @ICMRDELHI @drharshvardhan @ARanganathan72 @ShamikaRavi @TimesNow @ArvindKejriwal @RShivshankar @navikakumar
human recombinant erythropoietin(EPO)-improve outcome of seriously ill COVID-⬇️gravest sequelae.(1) improve respiration at several levels-lung,brainstem,spinal cord,respiratory(2) counteract inflam by cytokine storm(3)neuroprotective,neuroregenerative. htt
A thorough review on the potential for the red blood cell growth factor, erythropoietin in COVID-19 by Hannelore Ehrenreich, Karin Weissenborn, Martin Begemann, Markus Busch, Eduard Vieta & Kamilla W. Miskowiak. https://t.co/O52GiVhmRE https://t.co/1w9
RT @quantografo: Según los investigadores del Instituto Max Planck de Medicina Experimental en Gotinga, el agente antidopaje Epo también po…
Según los investigadores del Instituto Max Planck de Medicina Experimental en Gotinga, el agente antidopaje Epo también podría ser efectivo contra #COVID_19. https://t.co/BrDee0EvZx https://t.co/Fcek1DKP9f
Erythropoietin as candidate for supportive treatment of severe COVID-19. https://t.co/vEEHbGDMRi
@zubietajr @ResearchGate Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. http
@ironorehopper Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/E
@d_magpie Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/EBRqE1
@kavehkazemian Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/E
@cr3ativ2 Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/EBRqE1
@qeios Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/EBRqE1gDO
@ryanodinegrimes Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co
@ZwyerAlex Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shortly. https://t.co/EBRq
@cameronks @farid__jalali @srrezaie Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 Research design for a double-blind placebo-controlled randomized clinical trial including severely affected patients, which i
@TrevizanBau Max Planck Institute Erythropoietin as candidate for supportive treatment of severe COVID-19 Research design for a double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to start shor
Erythropoietin as candidate for supportive treatment of severe COVID-19. https://t.co/JQUzAWpxdb https://t.co/40e7TdR8Np